There is no shortage of myths about the cancellation of US foreign assistance. This includes the widely held misconception that PEPFAR is exempt from US aid cuts and the belief that grant terminations are just taking place in South Africa. Many of these falsehoods have been reinforced by US and South African officials. Spotlight and GroundUp dissect some of the most popular misconceptions.
After the US slashed global aid, the South African government stated that only 17% of its HIV spending relied on US funding. But some experts argue that US health initiatives had more bang for buck than the government’s programmes. Jesse Copelyn looks past the 17% figure, and considers how the health system is being affected by the loss of US money.
Medical aid schemes will be given collective power to negotiate prices, according to draft regulations published last week. While some see the move as an important step toward reining in private healthcare prices, others argue that they do not go far enough and are legally unsound. Chris Bateman spoke to several leading experts about the proposed reforms.
South Africa’s National Department of Health is still to outline a clear contingency plan as a US funding freeze puts lives at risk, spells job losses, and presents threats to keeping HIV and TB under control. Ufrieda Ho reports.
A coalition of health service organisations has warned that patients will lose access to life-saving treatment if the US withdraws health funding to South Africa. Certain HIV and TB-related health services are continuing for now under a limited waiver. But the waiver has failed to cover organisations that provide services, including HIV care, specifically to LGBTI people and people who inject drugs. Two PEPFAR-funded harm reduction centres have already closed their doors, as have health service organisations that support LGBTI people.
A timely report on governance in South Africa’s healthcare sector released last year identified several serious shortcomings. As the political and administrative wheels again start turning in 2025, Elri Voigt unpacks the report and asks if government is paying attention.
From the ongoing political and legal battles over NHI, to the far-reaching health impacts of political change in the United States, it is set to be another tumultuous year for healthcare in South Africa and around the globe. Here’s Spotlight’s top four healthcare questions for 2025.
Professor Lucy Gilson scooped the prestigious international Virchow Prize. She chats to Biénne Huisman about her upbringing, unexpected dive into the world of public health, and shares her thoughts on National Health Insurance. She says it will take more than money to fix our health system.
In South Africa, taking HIV treatment means taking one or more antiretroviral tablets a day. People in some other countries have the additional option of treatment in the form of two injections administered every two months. Elri Voigt unpacks why long-acting HIV treatment is not available in South Africa and asks why the push for HIV prevention jabs has been so much stronger than that for HIV treatment jabs.
Taking antiretrovirals to prevent HIV infection mostly still involves swallowing one or more pills a day. Some long-acting products that work for a month or two at a time have been approved but are not yet in wide use in South Africa. As delegates gathered for the 25th International AIDS Conference (AIDS 2024) last week, Elri Voigt takes stock of the latest developments in this fast-moving field.
An HIV prevention injection that provides six months of protection per shot has been shown to be highly effective in a pivotal trial largely conducted in South Africa. There are however some concerns as to when the injection will become available and how widely. Thabo Molelekwa and Marcus Low report.
A trade unionist who spent years fighting for the rights of workers, the Free State‘s new health MEC Monyatso Mahlatsi now finds himself on the other side of the table where he might well be forced to make decisions that he would once have protested against. Refilwe Mochoari reports.
